News

Apply now for the ATCC Innovation Challenge

ATCC is excited to launch their 2025 Innovation Challenge, inviting researchers to explore bold, creative applications of their ThawReady™ Assay Ready Cells, an innovative line of products  designed to accelerate cell-based assays and eliminate the need for lengthy cell expansion and banking prior to starting bioassays, saving valuable time and money.

Running through November 30, 2025, the challenge offers researchers an opportunity to win free ThawReady™ products and gain visibility through collaboration with ATCC in webinars, conference showcases, and other scientific platforms. To enter, researchers must submit a short proposal (up to 1000 characters) describing how they plan to use ThawReady™ cells in their innovative research. Winning entries will receive complimentary products and the opportunity to share their work with the broader scientific community.

Two models are available for the challenge:

ThawReady™ THP-1 (TIB-202-AR)

  • Derived from a human monocytic leukemia patient.
  • Ideal for immunology, toxicology, and cancer research.
  • Supports assays such as monocyte differentiation, phagocytosis, and co-culture studies.
  • Preserved in a chemically defined, animal-free formulation.
  • Ready to use upon thawing with ≥80% viability.

 ThawReady™ THP-1 NF-κB-Luc2 (TIB-202-NFkB-LUC2-AR)

  • Engineered to express luciferase under NF-κB control.
  • Enables sensitive, quantitative analysis of NF-κB activation.
  • Demonstrates over 200-fold increase in luminescence upon LPS stimulation.
  • Maintains functionality and morphology post-thaw, even after extended rest periods.
  • Suitable for drug screening, pathway analysis, and biocompatibility testing.

 

Recent News

02/25/2026

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to treating MASH, obesity, and associated cardiometabolic diseases, today announced the appointment of Jorge Bartolome as Chief Executive Officer and member of the Board. He succeeds Allen Cunningham, a co-founder who will move to the role of Chief Operating Officer. Mr. Bartolome has over 25 years of

02/24/2026

Jeeva Clinical Trials Calls on Global Life Sciences Leaders to Modernize Infrastructure for AI-Driven Drug Development

Jeeva Clinical Trials today amplified its call to action for the global pharmaceutical and clinical research ecosystem: Artificial Intelligence will not transform drug development unless organizations modernize the IT infrastructure beneath it. The message — first articulated in a recent thought leadership article by Founder and CEO Harsha K. Rajasimha — has gained strong traction

02/24/2026

Liquet™ Medical Receives Second FDA 510(k) Clearance for Versus™ Catheter

Liquet Medical Inc., a pioneering medical device company committed to advancing patient care through innovative technologies, today announced it has received a second 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new configuration of the Versus™ Catheter. The latest clearance expands the company’s proprietary platform and opens access to a broader